CEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the contract research organization (CRO) that will run it and coming ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VIENNA, Va., June 18, 2024--CEL-SCI Corporation (NYSE American: CVM) today announced the Company’s Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled "Neoadjuvant ...

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Wednesday reported a loss of $7.5 million in its fiscal third quarter. VIENNA, Va., July 26, 2024--CEL-SCI’s phase 3 population analysis for upcoming ...